Clinical Trials
150 trialsNeoADAURA
AstraZeneca
SKYSCRAPER-06
Hoffmann-La Roche
MYSTIC
AstraZeneca
A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer
Hoffmann-La Roche
Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]
Hoffmann-La Roche
Nivolumab With or Without Ipilimumab or Chemotherapy in Treating Patients With Previously Untreated Stage I-IIIA Non-small Cell Lung Cancer
M.D. Anderson Cancer Center
POD1UM-304
Incyte Corporation
A Study Evaluating the Safety and Efficacy of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab, With or Without Platinum-Based Chemotherapy, in Participants With Previously Untreated Locally Advanced Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer
Hoffmann-La Roche
AcceleRET-Lung
Hoffmann-La Roche
CANOPY-1
Novartis
Nivolumab Plus Cisplatin/Pemetrexed or Cisplatin/Gemcitabine as Induction in Resectable Non-Small Cell Lung Cancer
Thomas Jefferson University
Efficacy, Safety, and Pharmacodynamics of Tislelizumab Monotherapy and Multiple Tislelizumab-based Immunotherapy Combinations in Participants With Resectable Non-Small Cell Lung Cancer
BeOne Medicines
Intratumoral Cisplatin for Resectable NSCLC
University of Vermont
Use of High Dose Radiation Followed by Chemotherapy and Radiation to Treat Locally Advanced NSCLC
Wake Forest University Health Sciences
MK-7684A-007
Merck Sharp & Dohme LLC
CheckMate 816
Bristol-Myers Squibb
CheckMate 9LA
Bristol-Myers Squibb
Platinum Doublet Chemotherapy and Proton Beam Radiation Therapy in Treating Patients With Stage II-III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery
Mayo Clinic
MK-3475A-D77
Merck Sharp & Dohme LLC
CheckMate 227
Bristol-Myers Squibb
Study of Durvalumab Given With Chemoradiation Therapy in Patients With Unresectable Non-small Cell Lung Cancer
AstraZeneca
LIBRETTO-431
Eli Lilly and Company
A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)
Bristol-Myers Squibb
A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer
Bristol-Myers Squibb
FLAURA2
AstraZeneca
Ociperlimab With Tislelizumab and Chemotherapy in Participants With Untreated Metastatic Non-Small Cell Lung Cancer
BeiGene
MK-3475A-D77
Merck Sharp & Dohme LLC
SQUIRE
Eli Lilly and Company
Hypofractionated Boost Before Chemoradiation for Patients With Stage II-III Non-small Cell Lung Cancer Unsuitable for Surgery
Ohio State University Comprehensive Cancer Center
CONTERNO
Checkpoint Therapeutics, Inc.
KEYNOTE-799
Merck Sharp & Dohme LLC
RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)
EpicentRx, Inc.
EURTAC
Spanish Lung Cancer Group
Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery
National Cancer Institute (NCI)
A Study Evaluating the Efficacy and Safety of Tislelizumab Versus Chemotherapy in Advanced Non-Squamous Non-small Cell Lung Cancer
BeiGene
Avelumab in First-line NSCLC (JAVELIN Lung 100)
EMD Serono
LDK378 Versus Chemotherapy in Previously Untreated Patients With ALK Rearranged Non-small Cell Lung Cancer
Novartis
GECP-SCAT
Spanish Lung Cancer Group
MK-3475-671
Merck Sharp & Dohme LLC
MK-3475-A86
Merck Sharp & Dohme LLC
MK-3475-789
Merck Sharp & Dohme LLC
Phalcis
Spanish Lung Cancer Group
MK-3475-189
Merck Sharp & Dohme LLC
KEYNOTE-782
Merck Sharp & Dohme LLC
A Study of Cisplatin + Pemetrexed + Avastin as First-Line Therapy
Columbia University
MK-3475-189
Merck Sharp & Dohme LLC
Selumetinib in Patients Receiving Pemetrexed and Platinum-based Chemotherapy in Advanced or Metastatic KRAS Wildtype or Unknown Non-Squamous NSCLC
Canadian Cancer Trials Group
GEOMETRY-E
Novartis
BREC
Spanish Lung Cancer Group
M7824 With cCRT in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)
EMD Serono